Perceptive Advisors LLC purchased a new stake in Evolus, Inc. (NASDAQ:EOLS - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 1,286,862 shares of the company's stock, valued at approximately $5,289,000. Perceptive Advisors LLC owned 1.95% of Evolus at the end of the most recent reporting period.
A number of other institutional investors also recently modified their holdings of the company. Larson Financial Group LLC grew its holdings in shares of Evolus by 136.6% during the fourth quarter. Larson Financial Group LLC now owns 4,914 shares of the company's stock worth $33,000 after buying an additional 2,837 shares in the last quarter. Meeder Asset Management Inc. bought a new stake in Evolus in the 4th quarter valued at approximately $34,000. Wexford Capital LP bought a new stake in Evolus in the 3rd quarter valued at approximately $37,000. Aquatic Capital Management LLC acquired a new position in Evolus during the 3rd quarter worth approximately $48,000. Finally, State of Wyoming acquired a new position in Evolus during the 4th quarter worth approximately $63,000. 90.69% of the stock is currently owned by institutional investors.
Evolus Stock Performance
NASDAQ:EOLS opened at $5.84 on Friday. The stock's 50-day simple moving average is $6.47 and its 200 day simple moving average is $5.49. The company has a market cap of $384.62 million, a P/E ratio of -8.72 and a beta of 1.32. Evolus, Inc. has a 52-week low of $3.86 and a 52-week high of $9.35.
Evolus (NASDAQ:EOLS - Get Free Report) last issued its quarterly earnings results on Monday, May 4th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.02). The company had revenue of $73.14 million during the quarter, compared to analysts' expectations of $72.52 million. During the same period in the previous year, the business earned ($0.30) earnings per share. As a group, equities analysts predict that Evolus, Inc. will post -0.38 earnings per share for the current fiscal year.
Analysts Set New Price Targets
A number of analysts have recently issued reports on EOLS shares. Weiss Ratings upgraded shares of Evolus from a "sell (e+)" rating to a "sell (d-)" rating in a report on Monday, June 15th. BTIG Research restated a "buy" rating and set a $13.00 target price on shares of Evolus in a report on Wednesday, June 17th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Evolus currently has a consensus rating of "Moderate Buy" and a consensus price target of $16.00.
Read Our Latest Research Report on EOLS
About Evolus
(
Free Report)
Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.
The company's flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.
See Also
Want to see what other hedge funds are holding EOLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Evolus, Inc. (NASDAQ:EOLS - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Evolus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evolus wasn't on the list.
While Evolus currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
